Clinical trials in Hamburg – page 16

1 128 clinical trials in Hamburg, Germany across 19 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Hamburg at a glance

1 128

clinical trials

Research sites19

Quick filters

1 128 trials in Hamburg

Open in trial search

Pancreatic carcinoma metastatic+1

Recruiting

A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

Registered drug

A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Gemcitabine
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Hypophosphatasia

Recruiting

A Study Testing the Safety and Tolerability of ALE1 in Healthy Adults and Adults with Hypophosphatasia

Investigational

A Study Testing the Safety and Tolerability of ALE1 in Healthy Adults and Adults with Hypophosphatasia

Investigational

Germany

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:ALE1
Sponsor:Alesta Therapeutics B.V.

Contact Research Centre

Allogenic stem cell transplantation

Recruiting

Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

Registered drugNo placebo

Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Blinatumomab
Sponsor:Ospedale Pediatrico Bambino Gesu

Contact Research Centre

Neurofibromatosis+1

Recruiting

A study of mirdametinib for infants and toddlers under 24 months of age with neurofibromatosis type 1 associated plexiform neurofibromas

InvestigationalNo placebo

A study of mirdametinib for infants and toddlers under 24 months of age with neurofibromatosis type 1 associated plexiform neurofibromas

InvestigationalNo placebo

Germany

Participants:0–17 years
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Breast cancer+3

Recruiting

A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment

Registered drugNo placebo

A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:Genentech Inc.

Contact Research Centre

A study testing RO7790121 for moderate to severe rheumatoid arthritis in patients who did not respond to or cannot tolerate TNF or JAK inhibitor treatments

Recruiting

Investigational

A study testing RO7790121 for moderate to severe rheumatoid arthritis in patients who did not respond to or cannot tolerate TNF or JAK inhibitor treatments

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Ro7790121
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Unicancer

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment

Investigational

A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Janssen Cilag International

Contact Research Centre

Atrial fibrillation

Recruiting

A Study to Test How Well PKN605 Works and How Safe It Is in Patients with Atrial Fibrillation

Investigational

A Study to Test How Well PKN605 Works and How Safe It Is in Patients with Atrial Fibrillation

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Novartis Pharma AG

Contact Research Centre

Endometrial cancer metastatic

Recruiting

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Azd8205
Sponsor:AstraZeneca AB

Contact Research Centre

Dermatitis atopic

Recruiting

A study to evaluate the long-term safety and effectiveness of afimkibart in patients with atopic dermatitis who took part in previous afimkibart studies

Investigational

A study to evaluate the long-term safety and effectiveness of afimkibart in patients with atopic dermatitis who took part in previous afimkibart studies

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Ro7790121
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:AstraZeneca AB

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Hamburg

What the registry says about research in the country

01 Oncology Research

Current clinical trials focusing on innovative treatments for metastatic prostate cancer, colorectal cancer, and breast cancer. Studies are evaluating new therapeutic combinations and targeted approaches for improved patient outcomes.

Advanced cancer therapies
Immunotherapy combinations
Treatment resistance strategies

02 Infectious Disease Prevention

Comprehensive vaccine development programs targeting respiratory syncytial virus, cytomegalovirus, and meningococcal infections. Research focuses on both adult and pediatric populations.

Vaccine immunogenicity
Long-term protection
Novel vaccine platforms

03 Neurological Conditions

Groundbreaking research in treating acute cerebral ischemic stroke with innovative therapies. Studies are evaluating functional outcomes and safety profiles of new therapeutic agents.

Stroke treatment
Neuroprotective strategies
Recovery outcomes

04 Women's Health

Clinical investigations addressing vaginal atrophy and contraceptive technologies. Research includes novel delivery systems and hormone-based treatments for postmenopausal conditions.

Reproductive health
Hormone therapy
Novel delivery systems

Back to Germany All countries